Home
Search
Study Topics
Glossary
|
|
|
|
|
Sponsors and Collaborators: |
Ontario Clinical Oncology Group (OCOG) Ontario Ministry of Health and Long Term Care |
---|---|
Information provided by: | Ontario Clinical Oncology Group (OCOG) |
ClinicalTrials.gov Identifier: | NCT00136864 |
Locally advanced non-small cell lung cancer, NSCLC, (Stage III) is potentially curable with aggressive combined modality therapy (chemotherapy and radiation). Conventional imaging can only evaluate gross anatomic abnormalities but functional imaging with positron emission tomography (PET) may more accurately identify patients who will benefit from aggressive combined modality therapy.
This prospective randomized clinical trial will enroll 400 patients that have undergone conventional staging for lung cancer and have been found to have Stage III NSCLC. The patients will then be randomized to either standard combined modality therapy for Stage III NSCLC or to PET imaging prior to combined modality therapy with curative intent. Based on the PET findings, patients will either be suitable for combined modality therapy with curative intent or not.
Condition | Intervention | Phase |
---|---|---|
Non-Small-Cell Lung Carcinoma |
Procedure: PET Diagnostic Imaging |
Phase III |
Study Type: | Interventional |
Study Design: | Diagnostic, Randomized, Open Label, Active Control, Parallel Assignment, Safety/Efficacy Study |
Official Title: | The Impact of Positron Emission Tomography (PET) Imaging in Stage III Non-small Cell Lung Cancer: A Prospective Randomized Clinical Trial (PET START Trial) |
Estimated Enrollment: | 400 |
Study Start Date: | August 2004 |
Estimated Study Completion Date: | May 2011 |
Estimated Primary Completion Date: | November 2009 (Final data collection date for primary outcome measure) |
Arms | Assigned Interventions |
---|---|
1: Experimental
PET Imaging
|
Procedure: PET Diagnostic Imaging
Patients in the PET group will undergo the standard diagnostic tests plus PET to determine those suitable for combined modality therapy
|
2: No Intervention
Standard Imaging
|
Ages Eligible for Study: | 18 Years and older |
Genders Eligible for Study: | Both |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Canada, Ontario | |
Princess Margaret Hospital | |
Toronto, Ontario, Canada, M5G 2M9 | |
Toronto-Sunnybrook Odette Regional Cancer Centre | |
Toronto, Ontario, Canada, M4N 3M5 | |
London Regional Cancer Centre | |
London, Ontario, Canada, N6A 4L6 | |
Juravinski Cancer Centre | |
Hamilton, Ontario, Canada, L8V 5C2 | |
Ottawa Hospital Regional Cancer Centre | |
Ottawa, Ontario, Canada, K1H 1C4 |
Study Chair: | Yee C Ung, MD | Toronto Sunnybrook Regional Cancer Centre |
Principal Investigator: | Mark N Levine, MD | Ontario Clinical Oncology Group |
Principal Investigator: | William Evans, MD | Juravinski Cancer Centre |
Responsible Party: | Ontario Clinical Oncology Group ( Dr. Mark Levine ) |
Study ID Numbers: | CTA-Control-087276 |
Study First Received: | August 25, 2005 |
Last Updated: | July 23, 2009 |
ClinicalTrials.gov Identifier: | NCT00136864 History of Changes |
Health Authority: | Canada: Health Canada |
Positron-Emission Tomography PET Scan Non-Small-Cell Lung Carcinoma Diagnosis Radiation Oncology |
Lung Cancer Randomized Controlled Trial Oncology Radiation Planning |
Thoracic Neoplasms Respiratory Tract Diseases Lung Neoplasms Lung Diseases |
Non-small Cell Lung Cancer Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |
Thoracic Neoplasms Respiratory Tract Neoplasms Neoplasms Neoplasms by Site Neoplasms by Histologic Type Respiratory Tract Diseases |
Lung Neoplasms Lung Diseases Carcinoma, Non-Small-Cell Lung Neoplasms, Glandular and Epithelial Carcinoma |